Clinical trials: Liver Cell Carcinoma Non-resectable
Advanced Unresectable Hepatocellular Carcinoma
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma.
- Trial name
- NCT07478302
- Testing
- SHR-2524 Injection, Bevacizumab Injection
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC
The study will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in first line setting in patients with unresectable hepatocellular carcinoma.
- Trial name
- Liver-NET1 (NCT05546879)
- Testing
- NP137, Atezolizumab, Bevacizumab
- Where
- 9 sites in France
- Volunteers
- 43 people
- Sponsor
- University Hospital, Grenoble
Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
This phase I/II trial studies the side effects and best dose of IDO1 inhibitor BMS-986205 (BMS-986205) when given together with nivolumab and how well it works as first or second line therapy in treating patients with liver…
- Conditions
- Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT03695250
- Testing
- IDO1 Inhibitor BMS-986205, Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Edward Kim
Carcinoma, Hepatocellular
Combination of Transcatheter Arterial Chemoembolization (TACE) and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma (HCC)
Most HCC patients are diagnosed at advanced stages in Korea, transcatheter arterial chemoembolization is considered a key modality for palliative treatment in these HCC patients.
- Trial name
- NCT00919009
- Testing
- TACE (Transcatheter Arterial Chemoembolization )
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- National Cancer Center, Korea
Carcinoma, Hepatocellular
Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma
To evaluate the efficacy and safety of conversion therapy in patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT06365034
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Qianfoshan Hospital
Hepatocellular Carcinoma
Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma
This is a single-arm phase II trial of Pembrolizumab (Keytruda) in patients with advanced, unresectable hepatocellular carcinoma.
- Trial name
- NCT02658019
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Lynn Feun, MD
Hepatocellular Carcinoma (HCC)
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
This is a multicenter, retrospective study planned to enroll patients with unresectable hepatocellular carcinoma (uHCC) who received first-line donafenib combined with an anti-PD-1/L1 monoclonal antibody and either TACE or HAIC…
- Trial name
- NCT07724951
- Testing
- Donafeinib, Transcatheter arterial chemoembolization, PD-1 / PD-L1 monoclonal antibody
- Where
- 8 sites in China
- Volunteers
- 400 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma Non-resectable
Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
It is a a single arm, observational clinical trial to evaluate the efficacy and safety of combination treatment with sintilimab injection plus endostar in untreated locally advanced or metastatic hepatocellular carcinoma.
- Trial name
- NCT03881501
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma Non-resectable
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
This study was designed to evaluate the effectiveness and safety of mFOLFOX7（Oxaliplatin,Calcium Levofolinate,Fluorouracil） combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.
- Trial name
- NCT06607107
- Testing
- mFOLFOX7 combined with Camrelizumab and apatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
The Overall Survival of Patients With Unresectable HCC in Real-life
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health…
- Trial name
- NCT03612726
- Where
- 3 sites in China, Hong Kong and 1 more
- Volunteers
- 5,000 people
- Sponsor
- Humanity & Health Medical Group Limited
Hepatocellular Carcinoma Non-resectable
HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
This is an open-label, single-arm, phase 2 study evaluating hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and cadonilimab as conversion therapy for initially unresectable hepatocellular carcinoma (HCC).
- Trial name
- CCGLC-011 (NCT06187961)
- Testing
- Hepatic arterial infusion chemotherapy (HAIC-FOLFOX), Lenvatinib, Cadonilimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma.
Dietary intervention with eicosapentaenoic acid combined with chemotherapy may shift inflammatory mediators toward resolution in non-resectable hepatocarcinoma and help to preserve muscle mass.
- Trial name
- NCT07664007
- Testing
- Eicosapentaenoic acid oral lipidic emulsion, Pacebo oral lipidic emulsion
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Instituto de Investigación Sanitaria Aragón
Unresectable Hepatocellular Carcinoma (HCC)
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT07408804
- Testing
- TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib), Lenvatinib
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- Bangladesh Medical University
Hepatocellular Carcinoma (HCC)
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
This is a single arm, open label, multi-center, phase 2 study to evaluate the safety and efficacy of sequential treatment with Melphalan/HDS followed by sorafenib in patients with unresectable hepatocellular carcinoma (HCC)…
- Trial name
- NCT02406508
- Testing
- Melphalan/HDS, Sorafenib
- Where
- 2 sites in United States
- Sponsor
- Delcath Systems Inc.
Hepatocellular Carcinoma
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
This is a prospective, single-armed, multicentric, explorative phase II clinical research of conversional therapy with combination of hepatic arterial infusion chemotherapy(HAIC), Donafenib Tosilate and Toripalimab for…
- Trial name
- NCT05493332
- Testing
- HAIC(FOLFOX), Oxaliplatin, Leucovorin
- Volunteers
- 93 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Adrenocortical Carcinoma, Brain and Central Nervous System Tumors
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells.
- Conditions
- Adrenocortical Carcinoma, Brain and Central Nervous System Tumors, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00002608
- Testing
- cisplatin, doxorubicin hydrochloride, tamoxifen citrate
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Regional Cancer Centre
Hepatocellular Carcinoma
Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma
The goal of this clinical trial is to evaluate the added value of 166Holmium SIRT to Atezolizumab-Bevacizumab in patients with non resectable HCC.
- Trial name
- HOLMBRAVE (NCT05705791)
- Testing
- QuiremSpheres
- Where
- 6 sites in France
- Volunteers
- 10 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Hepatocellular Carcinoma Non-resectable
Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
Pivotal Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT03533920
- Testing
- UNI-DEB
- Where
- 8 sites in South Korea
- Volunteers
- 62 people
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Unresectable Hepatocellular Carcinoma (HCC)
Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy
This is a Phase I/II, open-label, non-randomized, multicenter study to explore safety, tolerability and antitumor activity of NMS-01940153E as single agent in adult patients with unresectable hepatocellular carcinoma (HCC)…
- Trial name
- NCT05630937
- Testing
- NMS-01940153E
- Where
- 9 sites in United States, Italy and 1 more
- Volunteers
- 31 people
- Sponsor
- Nerviano Medical Sciences